3-(3-hydroxyphenyl)-2-[(E)-2-(3-methylphenyl)ethenyl]quinazolin-4(3H)-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(3-hydroxyphenyl)-2-[(E)-2-(3-methylphenyl)ethenyl]quinazolin-4(3H)-one
• 英文别名: 3-(3-hydroxyphenyl)-2-[(E)-2-(3-methylphenyl)ethenyl]quinazolin-4-one
• 化学式: C₂₃H₁₈N₂O₂
• 分子量: 354.4
• InChiKey: ACQFIOBLPYQSQF-OUKQBFOZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• QUINAZOLINONE ANTIBIOTICS
  申请人：UNIVERSITY OF NOTRE DAME DU LAC

  公开号：US20160031832A1

  公开（公告）日：2016-02-04

  A new class of antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA) is disclosed. Compounds of this class can impair cell-wall biosynthesis by binding to both the allosteric and the catalytic domains of penicillin-binding protein (PBP) 2a. This class of antibiotics holds promise in reversing obsolescence of staphylococcal PBPs as important targets for antibiotics. Embodiments of the invention thus provide novel antibacterial compounds that target penicillin-binding proteins and/or other important cellular targets. Methods for inhibiting the growth and/or replication of bacteria using the compounds described herein are also provided. Various embodiments exhibit activity against gram positive bacteria, including drug-resistant strains of Staphylococcus aureus.

  披露了一种新型抗生素，对甲氧西林耐药金黄色葡萄球菌（MRSA）有效。该类化合物可以通过结合青霉素结合蛋白（PBP）2a的变构和催化结构域来破坏细胞壁生物合成。这类抗生素有望扭转金黄色葡萄球菌PBP作为抗生素重要靶点的过时现象。因此，本发明实施例提供了针对青霉素结合蛋白和/或其他重要细胞靶点的新型抗菌化合物。还提供了使用所述化合物抑制细菌生长和/或复制的方法。各种实施例对革兰氏阳性菌表现出活性，包括耐药的金黄色葡萄球菌菌株。